Summary
Unable to verify most claims against the provided FDA label excerpts because the claims are largely about market/patent status and multiple safety/pharmacology comparisons not directly addressed in the supplied label text.
Category Scores
Accurate Statements
Acebutolol can cause hypoglycemia.
Supported indirectly by Sectral warning: “Diabetes and Hypoglycemia… β-blockers may potentiate insulin-induced hypoglycemia and mask some of its manifestations…” (Section 5 WARNINGS).
Unsupported Statements
Acebutolol was withdrawn by its original producer, Pfizer, in 2013.
Not supported in the provided FDA label excerpts (no market withdrawal, company actions, or dates are addressed).
Acebutolol discontinuation was due to sharply dropped sales.
Not supported in provided label excerpts.
Pfizer cited low market demand as the main reason for discontinuing acebutolol.
Not supported in provided label excerpts.
Acebutolol can cause bradycardia.
Bradycardia is listed as an adverse reaction in the provided label excerpt, but the claim does not specify Sectral/acebutolol correspondence explicitly; still, the label excerpt does support bradycardia as a cardiovascular adverse effect. Marking as unsupported due to missing explicit linkage in the provided prompt labeling context tying acebutolol to Sectral beyond the drug identification text.
Acebutolol can cause fatigue.
Fatigue is not mentioned in the provided adverse reactions/warnings excerpts.
Acebutolol can cause depression.
Depression is not mentioned in the provided label excerpts.
Acebutolol has a long-acting profile that increases the risk of arrhythmias in susceptible patients.
No such statement about long-acting profile or increased arrhythmia risk is present in the provided label excerpts.
Acebutolol has a narrow therapeutic window.
No therapeutic window statements are present in provided label excerpts.
Acebutolol was less favored by clinicians because of its adverse effects and narrow therapeutic window compared with alternatives with clearer safety profiles.
No comparative market adoption or clinician preference statements are present in provided label excerpts.
Acebutolol has lower potency in lowering blood pressure compared with metoprolol.
No comparative potency statements versus metoprolol are present in provided label excerpts.
Acebutolol has lower potency in lowering blood pressure compared with bisoprolol.
No comparative potency statements versus bisoprolol are present in provided label excerpts.
Acebutolol has modest β1 selectivity.
The provided label excerpts describe Sectral as “cardioselective” with “relative β1-selectivity” and ISA; however “modest” is not used verbatim and no degree/wording equivalence is provided.
Acebutolol offers less cardiac selectivity than many current agents.
No comparative selectivity statements versus other agents are present in provided label excerpts.
Acebutolol was less effective at managing hypertension compared with alternative beta-blockers.
No comparative effectiveness statements are present in provided label excerpts.
Acebutolol was less effective at managing angina compared with alternative beta-blockers.
No indication for angina or comparative angina effectiveness statements are present in provided label excerpts.
The original patent on acebutolol expired in 2006.
Not addressed in provided FDA label excerpts.
Generic versions of acebutolol never entered the market.
Not addressed in provided FDA label excerpts.
No generics were approved for acebutolol because the product had already been pulled.
Not addressed in provided FDA label excerpts.
No active generic or brand-name product for acebutolol remains on the market in the United States.
Not addressed in provided FDA label excerpts.
No active generic or brand-name product for acebutolol remains on the market in Europe.
Not addressed in provided FDA label excerpts.
Acebutolol is listed as discontinued on major drug databases.
Not addressed in provided FDA label excerpts.
Contradictions
Low
AI Statement
Acebutolol can cause bradycardia.
Label Reference
No direct contradiction found; however it is not clearly evaluated as supported due to linkage ambiguity in the provided content.
Important Omissions
If making safety claims (e.g., bradycardia, hypoglycemia), the label also includes specific contraindications (severe bradycardia, AV block, overt cardiac failure, cardiogenic shock) that should be reflected when discussing bradycardia risk.
Importance:
Moderate
For abrupt discontinuation risk in coronary artery disease, the label includes detailed tapering/observation instructions; none of the claims reflect this on-label warning.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Only one claim (hypoglycemia) is directly supported by the provided label excerpts; most other safety/efficacy comparisons and product-market statements are not supported by the provided FDA label text and therefore cannot be verified for safety accuracy here.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Misaligned
Primary Issue
Majority of claims are not supported by the provided FDA label excerpts (especially withdrawal/patent/market-availability statements and comparative potency/effectiveness/selectivity claims).
Suggested Improvement
Limit statements to what is explicitly supported in the provided Sectral (acebutolol HCl) label excerpts (e.g., contraindications list, hypoglycemia warning, and bradycardia as a listed cardiovascular adverse reaction if linkage is made explicit). Remove or separately source market/patent/discontinuation and cross-drug comparative efficacy/potency claims.